COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. Issue 6 (November 2021)
- Record Type:
- Journal Article
- Title:
- COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. Issue 6 (November 2021)
- Main Title:
- COVID-19 associated mucormycosis: A Descriptive Multisite Study from India
- Authors:
- Gupta, Ritesh
Kesavadev, Jothydev
Krishnan, Gopika
Agarwal, Sanjay
Saboo, Banshi
Shah, Meet
Mittal, Atul
Durani, Suhail
Luthra, Atul
Singhal, Anuj
Rasheed, Muhammed
Rao, G.V.S.
Tripathi, Vidit
Jha, Alka
Ghosh, Amerta
Mohan, V.
Singh, Awadhesh K.
Phatak, Sanjeev
Panicker, John
Bhadada, Sanjay Kumar
Joshi, Shashank
Pal, Rimesh
Mithal, Ambrish
Vikram, Naval
Misra, Anoop - Abstract:
- Abstract: Background and aims: Mucormycosis is an invasive fungal infection and carries a significant morbidity and mortality. A number of cases of mucormycosis have been reported in association with COVID-19. In this study, a consortium of clinicians from various parts of India studied clinical profile of COVID-19 associated mucormycosis (CAM) and this analysis is presented here. Methods: Investigators from multiple sites in India were involved in this study. Clinical details included the treatment and severity of COVID-19, associated morbidities, as well as the diagnosis, treatment and prognosis of mucormycosis. These data were collected using google spreadsheet at one centre. Descriptive analysis was done. Results: There were 115 patients with CAM. Importantly, all patients had received corticosteroids. Diabetes was present in 85.2% of patients and 13.9% of patients had newly detected diabetes. The most common site of involvement was rhino-orbital. Mortality occurred in 25 (21.7%) patients. On logistic regression analysis, CT scan-based score for severity of lung involvement was associated with mortality. Conclusion: Universal administration of corticosteroids in our patients is notable. A large majority of patients had diabetes, while mortality was seen in ∼1/5th of patients, lower as compared to recently published data. Highlights: All patients with COVID-19 associated mucormycosis (CAM, n 115) had received corticosteroids during treatment for COVID-19. Diabetes wasAbstract: Background and aims: Mucormycosis is an invasive fungal infection and carries a significant morbidity and mortality. A number of cases of mucormycosis have been reported in association with COVID-19. In this study, a consortium of clinicians from various parts of India studied clinical profile of COVID-19 associated mucormycosis (CAM) and this analysis is presented here. Methods: Investigators from multiple sites in India were involved in this study. Clinical details included the treatment and severity of COVID-19, associated morbidities, as well as the diagnosis, treatment and prognosis of mucormycosis. These data were collected using google spreadsheet at one centre. Descriptive analysis was done. Results: There were 115 patients with CAM. Importantly, all patients had received corticosteroids. Diabetes was present in 85.2% of patients and 13.9% of patients had newly detected diabetes. The most common site of involvement was rhino-orbital. Mortality occurred in 25 (21.7%) patients. On logistic regression analysis, CT scan-based score for severity of lung involvement was associated with mortality. Conclusion: Universal administration of corticosteroids in our patients is notable. A large majority of patients had diabetes, while mortality was seen in ∼1/5th of patients, lower as compared to recently published data. Highlights: All patients with COVID-19 associated mucormycosis (CAM, n 115) had received corticosteroids during treatment for COVID-19. Diabetes was present in 85.2% of patients with CAM. Pneumonia severity score on CT scan was associated with mortality due to CAM. … (more)
- Is Part Of:
- Diabetes & metabolic syndrome. Volume 15:Issue 6(2021)
- Journal:
- Diabetes & metabolic syndrome
- Issue:
- Volume 15:Issue 6(2021)
- Issue Display:
- Volume 15, Issue 6 (2021)
- Year:
- 2021
- Volume:
- 15
- Issue:
- 6
- Issue Sort Value:
- 2021-0015-0006-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-11
- Subjects:
- Diabetes -- Periodicals
Metabolism -- Disorders -- Periodicals
Diabetes Mellitus -- Periodicals
Metabolic Diseases -- Periodicals
Diabète -- Périodiques
Métabolisme, Troubles du -- Périodiques
Endocrinologie -- Périodiques
Diabète -- Physiopathologie -- Périodiques
Diabetes
Metabolism -- Disorders
Electronic journals
Periodicals
616.462 - Journal URLs:
- http://www.clinicalkey.com.au/dura/browse/journalIssue/18714021 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/18714021 ↗
http://www.sciencedirect.com/science/journal/18714021 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.dsx.2021.102322 ↗
- Languages:
- English
- ISSNs:
- 1871-4021
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3579.600509
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 20060.xml